# Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)

> **NCT03184402** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 124 (actual)

## Conditions studied

- Functional Dyspepsia

## Interventions

- **DRUG:** DWJ1252
- **DRUG:** Gasmotin
- **DRUG:** Placebo of Gasmotin
- **DRUG:** Placebo of DWJ1252

## Key facts

- **NCT ID:** NCT03184402
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-07-31
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184402, "Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03184402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*